ClinicalTrials.gg
RecruitingNCT07240961Updated Nov 21, 2025

Lumbal Erector Spinae Plane Block for Pain Management After Total Hip Arthroplasty

An interventional study of Lumbal Erector Spinae Plane Block and intravenous pain killers in Total Hip Arthroplasty (THA), sponsored by University Tunis El Manar. Recruiting at 1 site in Tunisia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by University Tunis El Manar · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The Erector Spinae Plane (ESP) block or spinal erector block was first described in September 2016 by a Canadian team. It's a block that was initially used for the treatment of chronic thoracic neuropathic pain. The ESP block is one of the inter-fascicular blocks and it's an easy-to-perform technique.In the literature, it has been reported that Lumbar ESPB provides effective analgesia after a hip surgery.

The purpose of this prospective randomized study was to compare the analgesic effects of the ultrasound-guided lumbar Erector Spinae Plane block on postoperative pain management versus the multimodal analgesia after total hip arthroplasty.

Read the detailed description

Patients aged more than 18 years, ASA I-III scheduled for primary total hip arthroplasty with lateral approach and under general anesthesia Patients were randomly assigned, into 1 of 2 groups, namely, group ESPBL and group Placebo, using sealed envelopes

  • For ESPBL group: Lumbar ESP block performed after anesthesia induction. A low-frequency ultrasound probe will be placed longitudinally 2-3 cm lateral to the L4 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and following confirmation of the correct position of the needle, between the erectorspinae muscle and the transverse process,30 ml of local anesthetic (0.25% bupivacaine/0.2% ropivacaine) will be administered for the block.
  • For Placebo group: patients had multimodal analgesia without lumbar ESP block Patients will be transferred to continuous care unit for 24 hours.

Post-operative analgesia will include:

  1. Paracetamol 1g IV every 8 hours for 1 day then oral paracetamol 1g every 8 hours for 4 weeks.
  2. Diclofenac sodium(50mg) 1 tablet x 2 per day for 5 days.
  3. PCA morphine (Patient Controlled Analgesia), as a rescue analgesia, programmed as: Bolus of 1mg/ refractory period of 10 min/ maximum dose set up at 10mg every 12h.

The primary outcome of the study is to compare postoperative opioids consumption in the first 24 postoperative hours.

Secondary endpoints:

Secondary outcomes are: intraoperative opioid consumption, postoperative pain scores, sitting position and adverse effects related to opioids.

02

Conditions studied

  • Total Hip Arthroplasty (THA)

Keywords

  • hip arthroplasty
  • Lumbal Erector Spinae Plane Block
  • pain managment
03

In context

Lead sponsor

University Tunis El Manar is the lead sponsor of 74 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • primary total hip arthroplasty with lateral approach and under general anesthesia .

Exclusion criteria

Exclusion Criteria:

    • or refusal to regional anesthesia

      • Contraindication to non-steroidal anti-inflammatory (NSAID's)
      • Allergy to opioids
      • Allergy to paracetamol
      • \< 30ml/min
      • Weight\<50 kg or >100kg
      • Psychiatric disorders and difficulty of communication
      • Lower limb neurological deficit
      • Patients undergoing bilateral or revision total hip replacement
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    hip arthroplasty with nerve block

    Lumbar ESP block performed after anesthesia induction. A low-frequency ultrasound probe will be placed longitudinally 2-3 cm lateral to the L4 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and following confirmation of the correct position of the needle, between the erectorspinae muscle and the transverse process,30 ml of local anesthetic (0.25% bupivacaine/0.2% ropivacaine) will be administered for the block

    Procedure: Lumbal Erector Spinae Plane Block

  • Placebo comparator
    hip arthroplasty with intravenous pain killers

    intravenous pain killers

    Procedure: intravenous pain killers

Interventions

  • ProcedureLumbal Erector Spinae Plane Block

    Lumbar ESP block performed after anesthesia induction. A low-frequency ultrasound probe will be placed longitudinally 2-3 cm lateral to the L4 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle (100 mm, 22G) will be inserted cranio-caudal direction and following confirmation of the correct position of the needle, between the erectorspinae muscle and the transverse process,30 ml of local anesthetic (0.25% bupivacaine/0.2% ropivacaine) will be administered for the block.

  • Procedureintravenous pain killers

    intravenous pain killers

06

What researchers measure

Primary outcomes

  1. morphine consumption

    total morphine dose

    Time frame: Day 1

Secondary outcomes

  1. pain scores

    numerical pain rating scale \[1 to 10 worse outcome\]

    Time frame: Hour 2, Hour 4, Hour 6, Hour 12, Hour 18, Hour 24 and on Day 2 and Day 7.

  2. intraoperative opioid consumption

    total fentanyl dose

    Time frame: end of surgery

  3. pain on sitting position

    numerical pain rating scale \[1 to 10 worse outcome\]

    Time frame: Day 1

  4. QR 9 score

    quality of recovery score \[0 to 18 best outcome\]

    Time frame: Day 2

  5. ROM

    Range of mouvement \[0° to 90°best outcome\]

    Time frame: Day 1

  6. pain during walk

    numerical pain rating scale \[1 to 10 worse outcome\]

    Time frame: Day 7

07

Study locations

1 of 1 sites recruiting
  • Kassab Orthopedic Institute
    Manouba, 2010, Tunisia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07240961
Lead sponsor
University Tunis El Manar
Responsible party
Olfa kaabachi, MD (professor, University Tunis El Manar) — Principal investigator
First posted
Nov 21, 2025
Start date
Nov 1, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 7, 2026 (estimated)
Last update
Nov 21, 2025

Study contacts

KAABACHI OLFA
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion